Iterion Therapeutics
Clinical-stage biotechnology company developing novel therapeutics targeting the Wnt pathway for liver cancer and colorectal cancer, spun out from University of Utah and Huntsman Cancer Institute.
Notes
Iterion Therapeutics is a clinical-stage biotechnology company developing novel therapeutics that target the Wnt signaling pathway for cancer treatment. The Wnt pathway is dysregulated in many cancers, particularly liver cancer (hepatocellular carcinoma) and colorectal cancer, but has been historically difficult to drug.
The company's lead program ITER-01 is designed to block aberrant Wnt signaling in cancer cells while sparing normal tissue. Iterion was spun out from research at the University of Utah and Huntsman Cancer Institute.
Iterion is backed by Portal Innovations, a life science venture ecosystem based in Chicago that provides capital and operational support to early-stage biotech companies.
Team
- Rahul Aras - CEO
- LinkedIn: linkedin.com/in/rahularas
- Scientific founders from University of Utah
Additional Research Findings
- Founded in 2019, headquartered in Houston, Texas
- University spinout: University of Utah, Huntsman Cancer Institute
- Portfolio company of Portal Innovations
- Clinical-stage development
- Wnt pathway targeting for cancer
- Focus on hepatocellular carcinoma (liver cancer)
- Also developing for colorectal cancer
- Novel approach to historically undruggable pathway
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |